Potential Research Questions

Which treatment might improve outcome in HFpEF?Which lifestyle intervention or medication can effectively reduce cardiovascular risk?Can we stratify patients at risk to find out who needs tight monitoring or more aggressive treatment?Can cardiovascular risk of medication be predicted?

Status Quo and Medical Need

Cardiovascular disease remains the leading single cause of death in large parts of the industrialized world. However, in some cardiovascular diseases, little progress has been made over the last couple years. Heart failure with preserved ejection fraction (HFpEF) is such an area, where unlike in HFrEF (Heart failure with reduced ejection fraction) current treatments show little effect.

Metabolic phenotyping technology from Biocrates has been helping to improve our understanding of metabolic factors contributing to cardiovascular morbidity and mortality. Among a wide range of research endeavours using Biocrates’ technology, Biocrates has teamed up with leading European institutes in the EU funded SysVascand BiomarCARE projects.

Relevant Metabolite Classes

Amino acids and biogenic amines:

Multiple amino acid metabolites have been suggested as predictors of outcome in heart failure